Arrowhead Pharmaceuticals, Inc. (0HI3.L) LSE

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Christopher R. Anzalone	Chairman, Chief Executive Officer & President	2.22M	1969
Bruce D. Given	Chief Medical Scientist	486,308	1954
James C. Hamilton	Chief Medical Officer and Head of R&D	987,213	1979
Daniel J. Apel	Chief Financial Officer	1.04M	1966
Patrick O'Brien	COO & Secretary	1.05M	1964
Aaron Tan	Head of Tax	0	N/A
Mark Davis	Founder and Founder & Director of Insert Therapeutics Inc & Calando	0	N/A
Mark Seefeld	Head of Toxicology & Vice President	0	1954
Tao Pei	Chief Scientific Officer	0	N/A
Vincent Anzalone	Head of Investor Relations & Vice President	0	N/A
Howard Lovy	Director of Communications	0	N/A

Name

Title

Pay

Year Born

Christopher R. Anzalone

Chairman, Chief Executive Officer & President

2.22M

1969

Bruce D. Given

Chief Medical Scientist

486,308

1954

James C. Hamilton

Chief Medical Officer and Head of R&D

987,213

1979

Daniel J. Apel

Chief Financial Officer

1.04M

1966

Patrick O'Brien

COO & Secretary

1.05M

1964

Aaron Tan

Head of Tax

N/A

Mark Davis

Founder and Founder & Director of Insert Therapeutics Inc & Calando

N/A

Mark Seefeld

Head of Toxicology & Vice President

1954

Tao Pei

Chief Scientific Officer

N/A

Vincent Anzalone

Head of Investor Relations & Vice President

N/A

Howard Lovy

Director of Communications

N/A

Description

Arrowhead Pharmaceuticals, Inc. is a U.S.-based company focused on developing innovative medicines for the treatment of challenging and difficult-to-treat diseases. The company's extensive development pipeline features several RNA interference (RNAi) therapeutic candidates. These include: ARO-AAT: Currently in Phase II clinical trials for liver diseases associated with alpha-1 antitrypsin deficiency. ARO-APOC3: Advancing through both Phase 2b and Phase 3 clinical studies for hypertriglyceridemia. ARO-ANG3: Undergoing Phase 2b clinical evaluation for dyslipidemia. ARO-HSD: Having successfully completed Phase 1/2 clinical trials for various liver diseases. ARO-ENaC2: In preclinical development for dyslipidemia linked to cystic fibrosis. ARO-C3: In Phase 1/2a clinical trials, designed to reduce the production of complement component 3. ARO-DUX4: A preclinical candidate targeting facioscapulohumeral muscular dystrophy. ARO-XDH: In Phase 1 clinical trials for refractory gout. ARO-COV: A preclinical program focused on COVID-19. ARO-RAGE: In Phase 1/2a clinical trials for muco-obstructive or inflammatory pulmonary conditions. ARO-MMP7: Also in Phase 1/2a clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). Beyond its proprietary programs, Arrowhead is actively involved in the development of other significant therapeutics: JNJ-3989: A subcutaneously administered RNAi therapeutic aimed at chronic hepatitis B virus infection. Olpasiran: Designed to decrease the synthesis of apolipoprotein A. ARO-AMG1: Targeting genetically validated pathways for cardiovascular disease. Arrowhead Pharmaceuticals maintains strategic licensing and research collaborations. It partners with Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics JNJ-75220795, ARO-JNJ2, and ARO-JNJ3, all of which target liver-expressed pathways. Additionally, the company has a research and license agreement with Takeda Pharmaceuticals U.S.A., Inc. for an RNAi therapeutic candidate intended for liver disease. Established in 1989, Arrowhead Pharmaceuticals, Inc. operates from its corporate headquarters in Pasadena, California.